This guide is for medical device manufacturers, labelers, regulatory affairs teams, and UDI compliance professionals that need to understand the history and current status of GUDID implementation. It is particularly useful for organizations entering the U.S. market, reviewing legacy device records, or comparing FDA’s UDI timeline with newer UDI systems internationally.
This guide focuses specifically on the GUDID implementation timeline, including the 2013 UDI Final Rule, original compliance dates by device category, subsequent enforcement delays for Class I and unclassified devices, and the completion of the phased rollout.
It does not cover GUDID data requirements, UDI assignment or labelling rules in detail, issuing agencies, submission methods, account setup, exceptions and alternatives, or technical GUDID integration.
Introduction
The U.S. Food and Drug Administration’s Unique Device Identification system has one of the longest-established UDI implementation histories globally.
FDA published its final UDI Rule on 24 September 2013, establishing requirements for device identification, UDI labelling and submission of specified device information to the Global Unique Device Identification Database (GUDID). Rather than requiring all devices to comply at once, FDA established a multi-year implementation schedule based primarily on device risk.
GUDID submission began with Class III devices in 2014, followed by implantable, life-supporting and life-sustaining devices in 2015, Class II devices in 2016, and eventually Class I and unclassified devices.
The final stage took longer than originally planned. Although the UDI Rule originally established 24 September 2018 as the GUDID compliance date for Class I and unclassified devices, FDA subsequently delayed enforcement. The general enforcement date for GUDID submission for applicable Class I and unclassified devices ultimately became 8 December 2022. Today, the original phased implementation schedule is complete. Understanding the historical dates remains important, however, because they explain when requirements became applicable to different device categories and help manufacturers interpret FDA’s current UDI framework.
GUDID Regulatory Foundation Timeline
24 September 2013: FDA Publishes the UDI Final Rule
The foundation of today’s GUDID requirements was established on 24 September 2013, when FDA published the final Unique Device Identification System Rule.
The rule established a UDI system intended to identify medical devices through distribution and use. Among its requirements, device labelers must submit specified information about devices subject to UDI requirements to GUDID.
FDA did not require all devices to comply immediately. Instead, the agency established a phased implementation schedule extending over several years, with higher-risk devices generally required to comply first.
Some provisions of the rule became effective on 24 October 2013, while others became effective on 23 December 2013. The major device-specific compliance deadlines followed later.
Key Takeaway
The GUDID timeline began with FDA’s 24 September 2013 UDI Final Rule, which established a phased implementation based primarily on device risk.
Class III GUDID Timeline
24 September 2014: Class III Requirements Begin
Class III medical devices and devices licensed under the Public Health Service Act were the first major category to reach the UDI compliance deadline.
Beginning 24 September 2014, applicable devices were required to meet several UDI requirements, including submission of specified device information to GUDID.
The same date also applied to UDI labelling, standard date formatting and applicable stand-alone software requirements.
This was the first major GUDID submission milestone, which was exactly one year after publication of the UDI Final Rule.
FDA’s original rule also allowed a labeler to request a one-year extension of this compliance date under the applicable regulatory provision, provided the request was submitted by the required deadline.
Key Takeaway
24 September 2014 was the first major GUDID compliance deadline, bringing applicable Class III and PHS Act devices into the database.
Implantable, Life-Supporting & Life-Sustaining Device Timeline
24 September 2015: I/LS/LS Requirements Begin
The second major milestone arrived on 24 September 2015.
From this date, applicable implantable, life-supporting and life-sustaining devices, regardless of their broader risk-class schedule, became subject to the relevant UDI requirements.
This included submission of required device information to GUDID.
The category is important because FDA accelerated implementation for these devices based on their clinical significance rather than simply waiting for the normal compliance date associated with their device class.
For example, an applicable Class II implantable device reached its GUDID compliance milestone in 2015 rather than waiting for the general Class II deadline in 2016.
Key Takeaway
Applicable implantable, life-supporting and life-sustaining devices reached their GUDID compliance date on 24 September 2015, regardless of the later general deadlines for some device classes.
Class II GUDID Timeline
24 September 2016: Class II Requirements Begin
The GUDID rollout expanded substantially on 24 September 2016, when the general compliance deadline arrived for Class II medical devices.
From this date, applicable Class II devices were required to have specified device information submitted to GUDID.
The milestone meant that, three years after publication of the final UDI Rule, the database requirements had expanded from the highest-risk devices to the much larger Class II device population.
Key Takeaway
24 September 2016 was the general GUDID compliance date for applicable Class II medical devices.
Class I & Unclassified Device Timeline
The final stage of GUDID implementation was more complicated because FDA delayed enforcement beyond the compliance date originally established in the UDI Rule.
24 September 2018: Original Compliance Date
Under the original UDI Rule, 24 September 2018 was the compliance date for applicable Class I devices and devices that had not been classified into Class I, II or III.
The rule required applicable devices to meet UDI labelling and GUDID data-submission requirements from this date.
However, FDA subsequently adopted enforcement policies that delayed implementation for many Class I and unclassified devices.
24 September 2022: Most Class I UDI Enforcement Begins
Following several extensions, FDA stated that it did not intend to enforce certain UDI requirements for Class I and unclassified devices, other than implantable, life-supporting or life-sustaining devices, before 24 September 2022.
This date applied to requirements including UDI labelling and standard date formatting.
GUDID submission received one additional short extension.
8 December 2022: General GUDID Enforcement Begins
FDA ultimately stated that it did not intend to enforce the GUDID submission requirement for applicable Class I and unclassified devices before 8 December 2022.
This additional 75-day period made 8 December 2022 the key final milestone in the general phased GUDID implementation schedule.
There is an important exception to understand. FDA’s current compliance policy states that it does not intend to enforce GUDID submission requirements for certain Class I devices considered consumer health products.
Therefore, while the overall phased rollout is complete, manufacturers should still determine whether a specific FDA enforcement policy, exception or alternative applies to their device.
Key Takeaway
The original GUDID compliance date for Class I and unclassified devices was 24 September 2018, but FDA delayed enforcement for applicable devices until 8 December 2022.
Direct Marking Timeline
Direct marking followed a separate schedule from GUDID data submission.
FDA generally requires a device to bear a UDI as a permanent marking when the device is intended to be used more than once and intended to be reprocessed before each use, subject to applicable exceptions and alternatives.
The original direct-marking schedule was:
| Device Category | Direct Marking Compliance Date |
|---|---|
| Life-supporting & life-sustaining | 24 September 2015 |
| Class III & PHS Act devices | 24 September 2016 |
| Class II | 24 September 2018 |
| Class I & unclassified | 24 September 2020 |
FDA subsequently issued enforcement policies affecting certain devices, particularly Class I and unclassified devices. For applicable Class I and unclassified devices other than life-supporting or life-sustaining devices, FDA stated that it did not intend to enforce direct-marking requirements before 24 September 2022.
Implantable devices are not subject to the UDI direct-marking requirement simply because they are implantable.
The distinction is important when reviewing historical compliance because GUDID submission, UDI labelling and direct marking did not always become applicable on the same date.
Key Takeaway
Direct marking followed its own phased schedule and, for some device categories, became applicable later than GUDID submission deadlines.
GUDID Timeline at a Glance
The major milestones in the U.S. GUDID rollout can be summarized as follows:
| Date | Major GUDID / UDI Milestone |
|---|---|
| 24 September 2013 | FDA publishes the UDI Final Rule |
| 24 October 2013 | Certain provisions of the UDI Rule become effective |
| 23 December 2013 | Remaining applicable provisions of the UDI Rule become effective |
| 24 September 2014 | Class III and PHS Act device GUDID compliance begins |
| 24 September 2015 | Implantable, life-supporting and life-sustaining device compliance begins |
| 24 September 2016 | General Class II GUDID compliance begins; Class III direct marking begins |
| 24 September 2018 | Original Class I/unclassified GUDID compliance date; Class II direct marking begins |
| 24 September 2020 | Original Class I/unclassified direct-marking compliance date |
| 24 September 2022 | FDA enforcement begins for certain Class I/unclassified UDI requirements following enforcement delays |
| 8 December 2022 | General GUDID submission enforcement begins for applicable Class I and unclassified devices following FDA’s final extension |
Which GUDID Date Applies to Your Device?
Because the main GUDID rollout is now complete, manufacturers generally do not need to determine a future phase-in date. Instead, the historical timeline helps establish how a device entered the UDI framework.
A useful way to evaluate a device is to ask:
- What is the device classification? This identifies the original class-based compliance date.
- Is it implantable, life-supporting or life-sustaining? These devices may have reached compliance earlier than their general device class.
- Is it Class I or unclassified? Distinguish the original 24 September 2018 compliance date from FDA’s later enforcement policies, including the 8 December 2022 GUDID milestone.
- Does a current exception, alternative or enforcement policy apply? The completion of the general phase-in does not mean every medical device is necessarily subject to identical GUDID requirements.
Conclusion
The GUDID implementation timeline spans nearly a decade of phased compliance and enforcement milestones.
FDA established the UDI system on 24 September 2013, followed by GUDID compliance for Class III devices in 2014, implantable, life-supporting and life-sustaining devices in 2015, and Class II devices in 2016.
Class I and unclassified devices had an original GUDID compliance date of 24 September 2018, but FDA subsequently delayed enforcement. The final major milestone came on 8 December 2022, when general GUDID submission enforcement began for applicable Class I and unclassified devices following FDA’s extensions.
The general phased implementation schedule is therefore complete. For manufacturers today, the focus is no longer on waiting for a future class-based deadline, but on determining whether a device is subject to GUDID submission and whether any current exception, alternative or FDA enforcement policy applies.
